COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee
Paul Turner, Ignacio J. Ansotegui, Dianne E. Campbell, Victòria Cardona, Motohiro Ebisawa, Yehia El‐Gamal, Stanley M. Fìneman, Mário Geller, Alexei Gonzalez‐Estrada, Paul A. Greenberger, Agnes Sze Yin Leung, Michael Levin, Antonella Muraro, Mario Sánchez Borges, Gianenrico Senna, Luciana Kase Tanno, Bernard Yu‐Hor Thong, Margitta Worm
Abstract
Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine. In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.